Euglycemic / Hyperglycemic Clamp Study
Discover how Melior’s unique phenotypic screening platforms can uncover the untapped value of your candidate therapeutic
The hyperinsulinemic/euglycemic clamp (glucose clamp) is the gold standard method for detecting insulin sensitivity and glucose utilization in experimental animals and in humans.
During the study, insulin is infused intravenously (IV) at a steady rate and blood glucose levels maintained at some predetermined level (e.g. 100 mg/dL for euglycemic state) by variable infusion of glucose. At steady-state, the glucose infusion rate (GIR) is equal to whole-body glucose uptake and utilization.
Drugs, such as the thiazolidinones (PPARγ agonists; e.g. rosiglitazone) and MLR-1023 improve insulin sensitivity and thereby increase GIR in animals subjected to the euglycemic clamp. Other classes of diabetic agents such as sulfonylureas, DPP-4 inhibitors and SGLT2 inhibitors do not exhibit activity in a clamp study. Therefore, a glucose clamp is a useful tool to understand the mechanism of action for some metabolically active therapeutics or insulin sensitizers.
The actual glucose clamp procedure normally takes about 2-3 hours / animal. However, drugs such as thiazolidinediones (TZDs; e.g. rosiglitazone) can require dosing for a week or more to achieve maximal effect. Also, Melior does normally complete the clamp procedure on all study animals over two or more days. Therefore, a typical clamp study typically takes 2 or more weeks to complete. Groups sizes are normally 6 to 10 animals.